Assessing consumer gains from a drug price control policy in the U.S.:
"This paper uses national data for the period 1960 to 2000 to estimate an aggregate private consumer demand for pharmaceuticals in the U.S. The estimated demand curve is then used to simulate the value of consumer surplus gains from a drug price control regime that holds drug price increases to...
Gespeichert in:
Hauptverfasser: | , |
---|---|
Format: | Buch |
Sprache: | English |
Veröffentlicht: |
Cambridge, Mass.
National Bureau of Economic Research
2005
|
Schriftenreihe: | National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series
11139 |
Schlagworte: | |
Online-Zugang: | Volltext |
Zusammenfassung: | "This paper uses national data for the period 1960 to 2000 to estimate an aggregate private consumer demand for pharmaceuticals in the U.S. The estimated demand curve is then used to simulate the value of consumer surplus gains from a drug price control regime that holds drug price increases to the same rate of growth as the general consumer price level over the time period from 1981 to 2000. Based upon a 7 percent real interest rate, we find that the future value of consumer surplus gains from this hypothetical policy would have been |
Beschreibung: | 27 S. graph. Darst. |
Internformat
MARC
LEADER | 00000nam a2200000zcb4500 | ||
---|---|---|---|
001 | BV023591258 | ||
003 | DE-604 | ||
005 | 20100222 | ||
007 | t | ||
008 | 051103s2005 xxud||| |||| 00||| eng d | ||
035 | |a (OCoLC)58045432 | ||
035 | |a (DE-599)BVBBV023591258 | ||
040 | |a DE-604 |b ger | ||
041 | 0 | |a eng | |
044 | |a xxu |c XD-US | ||
049 | |a DE-521 |a DE-19 | ||
050 | 0 | |a HB1 | |
100 | 1 | |a Santerre, Rexford E. |e Verfasser |0 (DE-588)13045706X |4 aut | |
245 | 1 | 0 | |a Assessing consumer gains from a drug price control policy in the U.S. |c Rexford E. Santerre ; John A. Vernon |
264 | 1 | |a Cambridge, Mass. |b National Bureau of Economic Research |c 2005 | |
300 | |a 27 S. |b graph. Darst. | ||
336 | |b txt |2 rdacontent | ||
337 | |b n |2 rdamedia | ||
338 | |b nc |2 rdacarrier | ||
490 | 1 | |a National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series |v 11139 | |
520 | 3 | |a "This paper uses national data for the period 1960 to 2000 to estimate an aggregate private consumer demand for pharmaceuticals in the U.S. The estimated demand curve is then used to simulate the value of consumer surplus gains from a drug price control regime that holds drug price increases to the same rate of growth as the general consumer price level over the time period from 1981 to 2000. Based upon a 7 percent real interest rate, we find that the future value of consumer surplus gains from this hypothetical policy would have been | |
650 | 4 | |a Politik | |
650 | 4 | |a Drug Industry |x economics | |
650 | 4 | |a Drug and Narcotic Control |x economics | |
650 | 4 | |a Drug development |x Economic aspects | |
650 | 4 | |a Drugs |x Prices |x Government policy | |
650 | 4 | |a Fees, Pharmaceutical | |
700 | 1 | |a Vernon, John A. |e Verfasser |0 (DE-588)130457043 |4 aut | |
776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe |
830 | 0 | |a National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series |v 11139 |w (DE-604)BV002801238 |9 11139 | |
856 | 4 | 1 | |u http://papers.nber.org/papers/w11139.pdf |z kostenfrei |3 Volltext |
999 | |a oai:aleph.bib-bvb.de:BVB01-016906588 |
Datensatz im Suchindex
_version_ | 1804138248413380608 |
---|---|
adam_txt | |
any_adam_object | |
any_adam_object_boolean | |
author | Santerre, Rexford E. Vernon, John A. |
author_GND | (DE-588)13045706X (DE-588)130457043 |
author_facet | Santerre, Rexford E. Vernon, John A. |
author_role | aut aut |
author_sort | Santerre, Rexford E. |
author_variant | r e s re res j a v ja jav |
building | Verbundindex |
bvnumber | BV023591258 |
callnumber-first | H - Social Science |
callnumber-label | HB1 |
callnumber-raw | HB1 |
callnumber-search | HB1 |
callnumber-sort | HB 11 |
callnumber-subject | HB - Economic Theory and Demography |
ctrlnum | (OCoLC)58045432 (DE-599)BVBBV023591258 |
format | Book |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02064nam a2200409zcb4500</leader><controlfield tag="001">BV023591258</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20100222 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">051103s2005 xxud||| |||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)58045432</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV023591258</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">xxu</subfield><subfield code="c">XD-US</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-521</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">HB1</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Santerre, Rexford E.</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)13045706X</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Assessing consumer gains from a drug price control policy in the U.S.</subfield><subfield code="c">Rexford E. Santerre ; John A. Vernon</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge, Mass.</subfield><subfield code="b">National Bureau of Economic Research</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">27 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series</subfield><subfield code="v">11139</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">"This paper uses national data for the period 1960 to 2000 to estimate an aggregate private consumer demand for pharmaceuticals in the U.S. The estimated demand curve is then used to simulate the value of consumer surplus gains from a drug price control regime that holds drug price increases to the same rate of growth as the general consumer price level over the time period from 1981 to 2000. Based upon a 7 percent real interest rate, we find that the future value of consumer surplus gains from this hypothetical policy would have been</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Politik</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry</subfield><subfield code="x">economics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug and Narcotic Control</subfield><subfield code="x">economics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug development</subfield><subfield code="x">Economic aspects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Prices</subfield><subfield code="x">Government policy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fees, Pharmaceutical</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vernon, John A.</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)130457043</subfield><subfield code="4">aut</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series</subfield><subfield code="v">11139</subfield><subfield code="w">(DE-604)BV002801238</subfield><subfield code="9">11139</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">http://papers.nber.org/papers/w11139.pdf</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016906588</subfield></datafield></record></collection> |
id | DE-604.BV023591258 |
illustrated | Illustrated |
index_date | 2024-07-02T22:41:28Z |
indexdate | 2024-07-09T21:25:10Z |
institution | BVB |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016906588 |
oclc_num | 58045432 |
open_access_boolean | 1 |
owner | DE-521 DE-19 DE-BY-UBM |
owner_facet | DE-521 DE-19 DE-BY-UBM |
physical | 27 S. graph. Darst. |
publishDate | 2005 |
publishDateSearch | 2005 |
publishDateSort | 2005 |
publisher | National Bureau of Economic Research |
record_format | marc |
series | National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series |
series2 | National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series |
spelling | Santerre, Rexford E. Verfasser (DE-588)13045706X aut Assessing consumer gains from a drug price control policy in the U.S. Rexford E. Santerre ; John A. Vernon Cambridge, Mass. National Bureau of Economic Research 2005 27 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series 11139 "This paper uses national data for the period 1960 to 2000 to estimate an aggregate private consumer demand for pharmaceuticals in the U.S. The estimated demand curve is then used to simulate the value of consumer surplus gains from a drug price control regime that holds drug price increases to the same rate of growth as the general consumer price level over the time period from 1981 to 2000. Based upon a 7 percent real interest rate, we find that the future value of consumer surplus gains from this hypothetical policy would have been Politik Drug Industry economics Drug and Narcotic Control economics Drug development Economic aspects Drugs Prices Government policy Fees, Pharmaceutical Vernon, John A. Verfasser (DE-588)130457043 aut Erscheint auch als Online-Ausgabe National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series 11139 (DE-604)BV002801238 11139 http://papers.nber.org/papers/w11139.pdf kostenfrei Volltext |
spellingShingle | Santerre, Rexford E. Vernon, John A. Assessing consumer gains from a drug price control policy in the U.S. National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series Politik Drug Industry economics Drug and Narcotic Control economics Drug development Economic aspects Drugs Prices Government policy Fees, Pharmaceutical |
title | Assessing consumer gains from a drug price control policy in the U.S. |
title_auth | Assessing consumer gains from a drug price control policy in the U.S. |
title_exact_search | Assessing consumer gains from a drug price control policy in the U.S. |
title_exact_search_txtP | Assessing consumer gains from a drug price control policy in the U.S. |
title_full | Assessing consumer gains from a drug price control policy in the U.S. Rexford E. Santerre ; John A. Vernon |
title_fullStr | Assessing consumer gains from a drug price control policy in the U.S. Rexford E. Santerre ; John A. Vernon |
title_full_unstemmed | Assessing consumer gains from a drug price control policy in the U.S. Rexford E. Santerre ; John A. Vernon |
title_short | Assessing consumer gains from a drug price control policy in the U.S. |
title_sort | assessing consumer gains from a drug price control policy in the u s |
topic | Politik Drug Industry economics Drug and Narcotic Control economics Drug development Economic aspects Drugs Prices Government policy Fees, Pharmaceutical |
topic_facet | Politik Drug Industry economics Drug and Narcotic Control economics Drug development Economic aspects Drugs Prices Government policy Fees, Pharmaceutical |
url | http://papers.nber.org/papers/w11139.pdf |
volume_link | (DE-604)BV002801238 |
work_keys_str_mv | AT santerrerexforde assessingconsumergainsfromadrugpricecontrolpolicyintheus AT vernonjohna assessingconsumergainsfromadrugpricecontrolpolicyintheus |